EE183 Cost-Effectiveness Analysis of Early Versus Delayed Use of Abemaciclib Combination Treatment in Patients with HR+/HER2- High-Risk Early Breast Cancer: A US Payer Perspective
| Autor: | Chang, SH, Wang, HM, Wang, Y, Wilson, DL, Shao, H, Park, H |
|---|---|
| Zdroj: | In Value in Health July 2022 25(7) Supplement:S369-S369 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect